Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Exchange Rate Effect (2016 - 2019)

Coherus Oncology (CHRS) has disclosed Exchange Rate Effect for 6 consecutive years, with -$106000.0 as the latest value for Q4 2019.

  • Quarterly Exchange Rate Effect fell 176.81% to -$106000.0 in Q4 2019 from the year-ago period, while the trailing twelve-month figure was -$140000.0 through Mar 2020, down 140.58% year-over-year, with the annual reading at -$276000.0 for FY2019, 158.97% down from the prior year.
  • Exchange Rate Effect hit -$106000.0 in Q4 2019 for Coherus Oncology, down from $59000.0 in the prior quarter.
  • In the past five years, Exchange Rate Effect ranged from a high of $226000.0 in Q2 2018 to a low of -$271000.0 in Q4 2016.
  • Historically, Exchange Rate Effect has averaged -$12100.0 across 5 years, with a median of -$28000.0 in 2015.
  • Biggest five-year swings in Exchange Rate Effect: soared 2071.43% in 2018 and later tumbled 946.15% in 2019.
  • Year by year, Exchange Rate Effect stood at $82000.0 in 2015, then crashed by 430.49% to -$271000.0 in 2016, then skyrocketed by 97.42% to -$7000.0 in 2017, then skyrocketed by 2071.43% to $138000.0 in 2018, then crashed by 176.81% to -$106000.0 in 2019.
  • Business Quant data shows Exchange Rate Effect for CHRS at -$106000.0 in Q4 2019, $59000.0 in Q3 2019, and -$93000.0 in Q2 2019.